147 related articles for article (PubMed ID: 18979492)
1. Modeling of the intestinal peptide transporter hPepT1 and analysis of its transport capacities by docking and pharmacophore mapping.
Pedretti A; De Luca L; Marconi C; Negrisoli G; Aldini G; Vistoli G
ChemMedChem; 2008 Dec; 3(12):1913-21. PubMed ID: 18979492
[TBL] [Abstract][Full Text] [Related]
2. Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.
Pedretti A; De Luca L; Marconi C; Regazzoni L; Aldini G; Vistoli G
Bioorg Med Chem; 2011 Aug; 19(15):4544-51. PubMed ID: 21741846
[TBL] [Abstract][Full Text] [Related]
3. Fragmental modeling of human glutamate transporter EAAT1 and analysis of its binding modes by docking and pharmacophore mapping.
Pedretti A; De Luca L; Sciarrillo C; Vistoli G
ChemMedChem; 2008 Jan; 3(1):79-90. PubMed ID: 17990250
[TBL] [Abstract][Full Text] [Related]
4. Modelling of full-length human alpha4beta2 nicotinic receptor by fragmental approach and analysis of its binding modes.
Pedretti A; Marconi C; Bolchi C; Fumagalli L; Ferrara R; Pallavicini M; Valoti E; Vistoli G
Biochem Biophys Res Commun; 2008 May; 369(2):648-53. PubMed ID: 18302933
[TBL] [Abstract][Full Text] [Related]
5. In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors.
Ekins S; Johnston JS; Bahadduri P; D'Souza VM; Ray A; Chang C; Swaan PW
Pharm Res; 2005 Apr; 22(4):512-7. PubMed ID: 15846457
[TBL] [Abstract][Full Text] [Related]
6. Conformational restrictions in ligand binding to the human intestinal di-/tripeptide transporter: implications for design of hPEPT1 targeted prodrugs.
Våbenø J; Nielsen CU; Steffansen B; Lejon T; Sylte I; Jørgensen FS; Luthman K
Bioorg Med Chem; 2005 Mar; 13(6):1977-88. PubMed ID: 15727852
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidomimetic ketomethylene isosteres as pro-moieties for drug transport via the human intestinal di-/tripeptide transporter hPEPT1: design, synthesis, stability, and biological investigations.
Våbenø J; Nielsen CU; Ingebrigtsen T; Lejon T; Steffansen B; Luthman K
J Med Chem; 2004 Sep; 47(19):4755-65. PubMed ID: 15341490
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of N-methyl amide tripeptidomimetics as substrates for the human intestinal di-/tri-peptide transporter hPEPT1.
Andersen R; Nielsen CU; Begtrup M; Jørgensen FS; Brodin B; Frokjaer S; Steffansen B
Eur J Pharm Sci; 2006 Jul; 28(4):325-35. PubMed ID: 16713701
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of tripeptidic promoieties targeting the intestinal peptide transporter hPEPT1.
Thorn K; Andersen R; Christensen J; Jakobsen P; Nielsen CU; Steffansen B; Begtrup M
ChemMedChem; 2007 Apr; 2(4):479-87. PubMed ID: 17407174
[TBL] [Abstract][Full Text] [Related]
11. QSAR models for the human H(+)/peptide symporter, hPEPT1: affinity prediction using alignment-independent descriptors.
Larsen SB; Jørgensen FS; Olsen L
J Chem Inf Model; 2008 Jan; 48(1):233-41. PubMed ID: 18092768
[TBL] [Abstract][Full Text] [Related]
12. Modeling of human ghrelin receptor (hGHS-R1a) in its close state and validation by molecular docking.
Pedretti A; Vistoli G
Bioorg Med Chem; 2007 Apr; 15(8):3054-64. PubMed ID: 17329109
[TBL] [Abstract][Full Text] [Related]
13. Molecule-pharmacophore superpositioning and pattern matching in computational drug design.
Wolber G; Seidel T; Bendix F; Langer T
Drug Discov Today; 2008 Jan; 13(1-2):23-9. PubMed ID: 18190860
[TBL] [Abstract][Full Text] [Related]
14. Discovery of ligands for the human intestinal Di-/Tripeptide transporter (hPEPT1) using a QSAR-assisted virtual screening strategy.
Larsen SB; Omkvist DH; Brodin B; Nielsen CU; Steffansen B; Olsen L; Jørgensen FS
ChemMedChem; 2009 Sep; 4(9):1439-45. PubMed ID: 19557803
[TBL] [Abstract][Full Text] [Related]
15. Binding mode analyses and pharmacophore model development for sulfonamide chalcone derivatives, a new class of alpha-glucosidase inhibitors.
Bharatham K; Bharatham N; Park KH; Lee KW
J Mol Graph Model; 2008 Jun; 26(8):1202-12. PubMed ID: 18096420
[TBL] [Abstract][Full Text] [Related]
16. Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models.
Boppana K; Dubey PK; Jagarlapudi SA; Vadivelan S; Rambabu G
Eur J Med Chem; 2009 Sep; 44(9):3584-90. PubMed ID: 19321235
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides.
Flaten GE; Kottra G; Stensen W; Isaksen G; Karstad R; Svendsen JS; Daniel H; Svenson J
J Med Chem; 2011 Apr; 54(7):2422-32. PubMed ID: 21401113
[TBL] [Abstract][Full Text] [Related]
18. Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
Vig BS; Stouch TR; Timoszyk JK; Quan Y; Wall DA; Smith RL; Faria TN
J Med Chem; 2006 Jun; 49(12):3636-44. PubMed ID: 16759105
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
[TBL] [Abstract][Full Text] [Related]
20. Construction of human ghrelin receptor (hGHS-R1a) model using a fragmental prediction approach and validation through docking analysis.
Pedretti A; Villa M; Pallavicini M; Valoti E; Vistoli G
J Med Chem; 2006 Jun; 49(11):3077-85. PubMed ID: 16722627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
